{
    "Clinical Trial ID": "NCT00494481",
    "Intervention": [
        "干预一:",
        "加油 加油 加油 加油",
        "",
        "干预2:",
        "安慰剂 Plus Docetaxel",
        "可乐与多西达克斯"
    ],
    "Eligibility": [
        "融入标准:",
        "女性有乳腺癌的 histological/cytological确认。",
        "具有可测量的损伤或骨骼损伤的受试者",
        "排除标准:",
        "6周内放射治疗",
        "重大心脏事件、心律失调或其他心脏病"
    ],
    "Results": [
        "测量结果:",
        "患有疾病进展事件的患者数量",
        "客观疾病进展或死亡的患者数量(由于任何原因而没有客观进展)",
        "时间框架:RECIST肿瘤评估在筛查(在第1剂量之前3周内)进行,然后按临床实践现场进行,直到客观进展。",
        "结果一:",
        "手臂/组名称:Vandetanib PlusDocetaxel",
        "手臂/群组描述:瓦德塔尼布 100 mg 加上多西塔克塞尔",
        "分析的参与者总数: 35",
        "尺寸类型: 数字",
        "测量单位:参与者24人",
        "结果二:",
        "手臂/组名称:Placebo Plus Docetaxel",
        "手臂/群组描述:安慰剂和多西塔克尔",
        "分析的参与者总数: 29",
        "尺寸类型: 数字",
        "单位:参与者18人"
    ],
    "Adverse Events": [
        "意外事件一:",
        "总数: 14/33 (42.42%)",
        "内分裂症 4/33 (12.12%)",
        "发烧性中性衰竭 3/33 (9.09%)",
        "细胞分裂症 0/33 (0.00%)",
        "心肌梗塞 1/33 (3.03%)",
        "头晕 1/33 (3.03%)",
        "甲状腺炎 1/33 (3.03%)",
        "糖尿病 3/33 (9.09%)",
        "毛病 0/33 (0.00%)",
        "黄金 1/33 (3.03%)",
        "恶心 1/33 (3.03%)",
        "口腔炎 1/33 (3.03%)",
        "阿斯特尼亚 1/33 (3.03%)",
        "疲劳 1/33 (3.03%)",
        "不利事件二:",
        "总数: 12/29 (41.38%)",
        "中性衰竭 2/29 (6.90%)",
        "发烧性中毒性 1/29 (3.45%)",
        "细胞分裂症 1/29(3.45%)",
        "心血管振动 1/29 (3.45%)",
        "黑暗 0/29 (0.00%)",
        "0/29 (0.00%)",
        "白癜风 0/29 (0.00%)",
        "结肠炎 1/29(3.45%)",
        "阿尔及利亚 0/29 (0.00%)",
        "发病 0/29 (0.00%)",
        "口腔炎 0/29 (0.00%)",
        "阿斯特尼亚 0/29 (0.00%)",
        "疲劳 0/29 (0.00%)",
        "皮埃克西亚 1/29 (3.45%)"
    ]
}